ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BFRI vs ABBV // FREE CASH FLOW YIELD

Biofrontera Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: BFRI 1 — ABBV 7
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BFRI VS. ABBV) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BFRI ABBV SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 70.20% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 29.00% -64.00 ABBV /roic <GO>
EV/EBITDA & P/E Valuation — 33.3x — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE — 3.47% — TIE /fcf-yield <GO>
Operating Margin -27.20% 24.60% -51.80 ABBV /operating-margins <GO>
Net Profit Margin -25.30% 6.90% -32.20 ABBV /net-margins <GO>
Revenue Growth (YoY) 11.70% 8.60% +3.10 BFRI /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.27% -2.27 ABBV /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.33 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 7/9 -4.00 ABBV /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 42.2 65.1 -22.89 ABBV /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.15 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 113.1x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $13.8M $513.86B -$513.85B ABBV /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BFRI REV ABBV REV BFRI GROSS % ABBV GROSS % BFRI FCF ABBV FCF
FY 2025 $41.7M $61.16B — 70.2% -$13.4M $17.82B
FY 2024 $37.3M $56.33B — 70.0% -$10.3M $17.83B
FY 2023 $34.1M $54.32B — — -$24.9M $20.39B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BFRI // BETA —
ABBV // BETA 1.15